Komori
Fuso Pharmaceutical Industries (4538) · PolicyUpdated the performance-linked metrics and results for the current fiscal year

Executive Compensation Systems Focused on Enhancing Corporate Value over the Medium to Long Term

First written in FY2019. 2 of 8 entries say "Advanced", first in FY2020. Latest entry: FY2026.

8entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019AdvancedFY2020 – FY2021OtherFY2022 – FY20262019: 120192020: 120202021: 120212022: 120222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies

0 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026Updated the performance-linked metrics and results for the current fiscal yearAnnual report

    「The selected performance metrics for the fiscal year consisted of ordinary profit of ¥3.3 billion and net income of ¥2.3 billion in the initial plan, compared with actual ordinary profit of ¥2,349 million and net income of ¥2,011 million for the fiscal year.」

    Ordinary profit and net income are used as metrics for performance-linked remuneration, and the initial plan and actual results were disclosed. Actual ordinary profit was ¥2,349 million and net income was ¥2,011 million.
  2. FY2025Updated the performance-linked metrics and results for the current fiscal yearAnnual report

    「The selected performance metrics for the fiscal year consisted of ordinary profit of ¥2.3 billion and net income of ¥1.7 billion in the initial plan, compared with actual ordinary profit of ¥3,780 million and a net loss of ¥3,288 million for the fiscal year.」

    Ordinary profit, net income and other metrics are used for performance-linked remuneration, and the initial plan and actual results for the fiscal year are disclosed. Ordinary profit exceeded the plan, while patent litigation-related losses resulted in a net loss for the fiscal year.
  3. FY2024Updated the performance-linked metrics and results for the current fiscal yearAnnual report

    「The selected performance metrics for the fiscal year consisted of ordinary profit of ¥2.0 billion and net income of ¥1.3 billion in the initial plan, compared with actual ordinary profit of ¥1,868 million and net income of ¥1,377 million for the fiscal year.」

    Ordinary profit and net income are used as metrics for performance-linked remuneration, and the initial plan and actual results for the fiscal year are disclosed.
  4. FY2023Updated the performance-linked metrics and results for the current fiscal yearAnnual report

    「The selected performance metrics for the fiscal year consisted of ordinary profit of ¥1.6 billion and net income of ¥1.1 billion in the initial plan, compared with actual ordinary profit of ¥2,215 million and net income of ¥1,605 million for the fiscal year.」

    Ordinary profit and net income are used as metrics for performance-linked remuneration, and the initial plan and actual results for FY2023 are disclosed.
  5. FY2022Updated the performance-linked metrics and results for the current fiscal yearAnnual report

    「The selected performance metrics for the fiscal year consisted of ordinary profit of ¥1.1 billion and net income of ¥700 million in the initial plan, compared with actual ordinary profit of ¥1,996 million and net income of ¥1,483 million for the fiscal year.」

    Ordinary profit and net income are used as metrics for performance-linked remuneration, and the initial plan and actual results for the fiscal year are disclosed.
  6. FY2021AdvancedAnnual report

    「The selected performance metrics for the fiscal year consisted of ordinary profit of ¥1.5 billion and net income of ¥1.1 billion in the initial plan, compared with actual ordinary profit of ¥2,227 million and net income of ¥1,607 million for the fiscal year.」

    Ordinary profit and net income are used as metrics for performance-linked remuneration, and the initial plan and actual results for the fiscal year are disclosed.
  7. FY2020AdvancedAnnual report

    「The remuneration committee calculates the remuneration and other compensation for directors and submits its recommendations to the Representative Director and President. The Representative Director and President, who has been delegated authority by the Board of Directors, determines the remuneration amounts for each director based on the remuneration committee's recommendations.」

    The company moved from a policy of establishing a remuneration committee to the operational stage of actually calculating, recommending and determining remuneration amounts.
  8. FY2019First statedAnnual report

    「The policy governing the amount of executive remuneration and other compensation and the method for determining it provides that director remuneration is designed to encourage contributions to improved performance over the medium to long term, rather than only in the short term, thereby enabling continued enhancement of corporate value.」

    The policy expressly states that executive remuneration is designed to encourage contributions not only to short-term performance but also to improved medium- to long-term performance and corporate value. Director remuneration includes fixed remuneration, performance-linked remuneration and retirement allowances, but the payment ratio, metrics and base amounts for performance-linked remuneration are not clearly specified.
Moved together

"Response to the Generic Drug Market and Sales Promotion" moved the same way as this thread, in the same document, in 2 of its 8 moves.

2★1
  1. ★This thread
  2. 1Response to the Generic Drug Market and Sales Promotion2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Executive Compensation Systems Focused on Enhancing Corporate Value over the Medium to Long Term | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori